Literature DB >> 18510958

Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion.

Michalis I Hamilos1, Miodrag Ostojic, Branko Beleslin, Dragan Sagic, Ljubco Mangovski, Sinisa Stojkovic, Milan Nedeljkovic, Dejan Orlic, Bratislav Milosavljevic, Dragan Topic, Nevena Karanovic, William Wijns.   

Abstract

OBJECTIVES: The aim of our study was to compare coronary vasomotion after implantation of a second-generation biolimus A9-eluting stent (BES) and of a sirolimus-eluting stent (SES).
BACKGROUND: Drug-eluting stents (DES) have been associated with impaired local coronary vasomotion, delayed endothelialization, and increased late thrombotic risk. New DES with different drugs, pharmacokinetics, and polymers have been developed.
METHODS: Nineteen patients with a BES and 15 patients with a SES were studied 9 months after stent implantation. Endothelium-dependent and -independent coronary vasomotion were tested proximally and distally to the stent as well as at a reference segment during right atrial pacing at increasing heart rates. Quantitative coronary angiographic measurements were performed offline.
RESULTS: Of the patients with BES, 2 showed vasoconstriction with increased heart rate and 17 showed vasodilatation. Of the patients with a SES, 9 showed vasoconstriction while 6 showed vasodilatation. The SES showed significant vasoconstriction at both the proximal (-2.3 +/- 10% vs. 7.9 +/- 10%) and the distal (-5.4 +/- 9% vs. 6.1 +/- 8%) segments to the stent compared with the BES (p = 0.003 for proximal, p < 0.001 for distal segment). Endothelium-independent vasomotion after intracoronary nitrates did not differ significantly between the 2 groups (p = NS for proximal and distal segment).
CONCLUSIONS: Unlike the case with the SES, endothelium-dependent vasomotion at adjacent stent segments seems to be preserved after BES implantation. This result may be explained by the different drug release kinetics, DES design, or characteristics of polymer used in the stent system.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18510958     DOI: 10.1016/j.jacc.2007.12.059

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  28 in total

Review 1.  Restenosis after PCI. Part 2: prevention and therapy.

Authors:  J Wouter Jukema; Tarek A N Ahmed; Jeffrey J W Verschuren; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2011-10-11       Impact factor: 32.419

2.  The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK Study.

Authors:  Miodrag C Ostojic; Zoran Perisic; Dragan Sagic; Robert Jung; Yan-Ling Zhang; Jamie Bendrick-Peart; Ronald Betts; Uwe Christians
Journal:  Eur J Clin Pharmacol       Date:  2010-10-09       Impact factor: 2.953

3.  Effect of a novel peptide, WKYMVm- and sirolimus-coated stent on re-endothelialization and anti-restenosis.

Authors:  Eun-Jae Jang; In-Ho Bae; Dae Sung Park; So-Youn Lee; Kyung Seob Lim; Jun-Kyu Park; Jae-Won Shim; Doo Sun Sim; Myung Ho Jeong
Journal:  J Mater Sci Mater Med       Date:  2015-10-05       Impact factor: 3.896

4.  One-year clinical outcomes of BioMatrix™-Biolimus A9™ eluting stent: the e-BioMatrix multicenter post marketing surveillance registry in India.

Authors:  Ashwin B Mehta; Praveen Chandra; Jamshed Dalal; Prabhakar Shetty; Devang Desai; K Chocklingam; Jayesh Prajapati; Pramod Kumar; Vilas Magarkar; Apurva Vasawada; B K Goyal; Viveka Kumar; V Suryaprakash Rao; Ramesh Babu; Pritesh Parikh; Upendra Kaul; Aruna Patil; Tushar Mhetre; Hrishikesh Rangnekar
Journal:  Indian Heart J       Date:  2013-09-23

Review 5.  Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis.

Authors:  Teruo Inoue; Kevin Croce; Toshifumi Morooka; Masashi Sakuma; Koichi Node; Daniel I Simon
Journal:  JACC Cardiovasc Interv       Date:  2011-10       Impact factor: 11.195

6.  The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy.

Authors:  Shin-ichiro Hayashi; Akitsugu Yamamoto; Fukka You; Kentaro Yamashita; Yuka Ikegame; Masahiro Tawada; Tamotsu Yoshimori; Shigeomi Shimizu; Shigeru Nakashima
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

Review 7.  New drug-eluting stent concepts.

Authors:  Rainer Wessely
Journal:  Nat Rev Cardiol       Date:  2010-03-02       Impact factor: 32.419

Review 8.  Effects of Catheterization on Artery Function and Health: When Should Patients Start Exercising Following Their Coronary Intervention?

Authors:  Andrea Tryfonos; Daniel J Green; Ellen A Dawson
Journal:  Sports Med       Date:  2019-03       Impact factor: 11.136

9.  The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study.

Authors:  Young-Hoon Jeong; Jin-Sin Koh; Min-Kyung Kang; Yeon-Jeong Ahn; In-Suk Kim; Yongwhi Park; Seok-Jae Hwang; Choong Hwan Kwak; Jin-Yong Hwang
Journal:  Korean J Intern Med       Date:  2010-06-01       Impact factor: 3.165

10.  Development and validation of a semi-automated assay for the highly sensitive quantification of Biolimus A9 in human whole blood using high-performance liquid chromatography-tandem mass spectrometry.

Authors:  Claudia Clavijo; Tobin Strom; Vanessa Moll; Ronald Betts; Yan Ling Zhang; Uwe Christians; Jamie Bendrick-Peart
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-08-21       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.